The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.

Provided herein are phosphorylated Dicer 1 (pDicer1) antibodies, including those that selectively bind Serine 1728 and/or Serine 1852. Further provided herein are methods of treating cancer by administering the pDicer1 antibodies alone or in combination with other therapies.

The invention generally provides improved compositions and methods for detecting, diagnosing, prognosing, and monitoring multiple myeloma, chronic lymphocytic leukemia, or B-cell non-Hodgkin lymphoma in a subject. In particular, the invention provides methods for detecting BCMA in subjects to reliably diagnose, predict survival, or monitor multiple myeloma, chronic lymphocytic leukemia, or B-cell non-Hodgkin lymphoma in the subject.

This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided.

The disclosure provides compositions and methods for identifying a cancer associated with an RASGRF1 gene fusion in a subject. The disclosure also includes methods of treating a subject who has been pre-selected by detecting an RASGRF1 gene fusion in a sample obtained from the subject.

The current disclosure provides for novel therapeutic methods by identifying patient populations that may be treated effectively by immunotherapies. Accordingly, aspects of the disclosure relate to a method for treating cancer in a subject comprising administering to the subject an immunotherapy after a biological sample from the subject has been analyzed for membrane-localized antigens (mAg).

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Provided herein are methods and articles of manufacture for use with cell therapy for the treatment of diseases or conditions, e.g., cancer, including for predicting and treating a toxicity. In some embodiments, the toxicity is related to cytokine release syndrome (CRS). The methods generally involve assessing a change in a factor indicative of tumor burden in a subject that is associated with and/or correlate to a risk of developing toxicity. In some aspects, the methods can be used to determine if the subject is at risk or likely at risk for developing a toxicity following administration of the cell therapy. Also provided are methods for treating a subject having a disease or condition, in some cases involving administration of the cell therapy, based on assessment of risk of developing a toxicity following administration of the therapy. Also provided herein are reagents and kits for performing the methods.

This document relates to methods and materials for assessing and/or treating mammals (e.g., humans) having multiple myeloma (MM). For example, methods and materials that can be used to determine whether or not a mammal (e.g., a human) having MM is likely to develop one or more therapy-related myeloid neoplasms (t-MNs) are provided. This document also relates to methods and materials for treating a mammal (e.g., a human) having MM where the treatment is selected based, at least in part, on whether or not the mammal is likely to develop one or more t-MNs.

The disclosed embodiment relates to a composition and system comprising Artificial Intelligence integrated molecular cytology and radiology for triaging of thyroid nodules. More particularly, the composition comprises of biomarkers WGA, Galectin-3, HBME-1 and MAA. The combination of Galectin-3 and WGA expression in cytology-based assay with USG images illustrated a sensitivity of 84% and 96% specificity in delineating benign and malignant nodules. The combination can differentiate cancer and benign nodules of indeterminate nodules with specificity of 93% and sensitivity of 80% using markers and USG. System uses Artificial Intelligence for triaging of thyroid nodules, including a preprocessed fusion model developed using a fully connected neural network. The preprocessed fusion model achieved an AUC of 0.71, which increased to 0.91 (sensitivity: 84%, specificity: 96%) when combined with post-processing scores. Incorporating clinical parameters of TIRAD Bethesda scores further improved the AUC to 0.98, with sensitivity and specificity of 95% and 96%, respectively.